MX346523B - Mejoras de cultivos celulares. - Google Patents

Mejoras de cultivos celulares.

Info

Publication number
MX346523B
MX346523B MX2016013989A MX2016013989A MX346523B MX 346523 B MX346523 B MX 346523B MX 2016013989 A MX2016013989 A MX 2016013989A MX 2016013989 A MX2016013989 A MX 2016013989A MX 346523 B MX346523 B MX 346523B
Authority
MX
Mexico
Prior art keywords
cell culture
mammalian cell
media
culture improvements
improved
Prior art date
Application number
MX2016013989A
Other languages
English (en)
Spanish (es)
Inventor
A Pla Itzcoatl
C Matuck Joseph
C Fann John
Schulz Christof
A Roy Nicole
F Bruton David
Mcintire James
Hsiang David CHANG Yu-
Seewoester Thomas
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39184386&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX346523(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX346523B publication Critical patent/MX346523B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/50—Soluble polymers, e.g. polyethyleneglycol [PEG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/74—Undefined extracts from fungi, e.g. yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/76—Undefined extracts from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2016013989A 2006-09-13 2007-09-13 Mejoras de cultivos celulares. MX346523B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84515806P 2006-09-13 2006-09-13
US87637406P 2006-12-21 2006-12-21
PCT/US2007/020027 WO2008033517A2 (en) 2006-09-13 2007-09-13 Cell culture improvements

Publications (1)

Publication Number Publication Date
MX346523B true MX346523B (es) 2017-03-23

Family

ID=39184386

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2016013989A MX346523B (es) 2006-09-13 2007-09-13 Mejoras de cultivos celulares.
MX2017003647A MX353340B (es) 2006-09-13 2007-09-13 Mejoras de cultivos celulares.
MX2009002748A MX2009002748A (es) 2006-09-13 2007-09-13 Mejoras de cultivos celulares.
MX2012004477A MX345141B (es) 2006-09-13 2007-09-13 Mejoras de cultivos celulares.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2017003647A MX353340B (es) 2006-09-13 2007-09-13 Mejoras de cultivos celulares.
MX2009002748A MX2009002748A (es) 2006-09-13 2007-09-13 Mejoras de cultivos celulares.
MX2012004477A MX345141B (es) 2006-09-13 2007-09-13 Mejoras de cultivos celulares.

Country Status (17)

Country Link
US (11) US8093045B2 (enExample)
EP (4) EP2527425A1 (enExample)
JP (3) JP5878682B2 (enExample)
KR (2) KR20090074040A (enExample)
CN (6) CN101663390B (enExample)
AU (1) AU2007294731B2 (enExample)
BR (1) BRPI0716762A2 (enExample)
CA (5) CA2842966A1 (enExample)
IL (1) IL197444A0 (enExample)
MX (4) MX346523B (enExample)
MY (4) MY185872A (enExample)
NO (1) NO20091439L (enExample)
NZ (2) NZ575328A (enExample)
RU (2) RU2518289C2 (enExample)
SG (3) SG174804A1 (enExample)
TW (4) TW201708537A (enExample)
WO (1) WO2008033517A2 (enExample)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
KR100317188B1 (ko) * 1996-02-09 2002-02-19 스타르크, 카르크 사람TNFα와결합하는사람항체
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US20040151722A1 (en) * 2002-07-19 2004-08-05 Abbott Biotechnology Ltd. Treatment of metabolic disorders using TNFalpha inhibitors
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TWI439284B (zh) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
EP1807111A4 (en) * 2004-10-08 2009-05-27 Abbott Biotech Ltd SYNCYTIAL RESPIRATORY VIRUS INFECTION (RSV)
AU2006246721B2 (en) 2005-05-16 2012-12-13 Abbvie Biotechnology Ltd Use of TNF inhibitor for treatment of erosive polyarthritis
NZ595340A (en) 2005-11-01 2013-04-26 Abbott Biotech Ltd Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
TW201333030A (zh) 2006-04-05 2013-08-16 Abbott Biotech Ltd 抗體之純化
WO2008063213A2 (en) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
WO2007120626A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of ankylosing spondylitis
EP2010214A4 (en) * 2006-04-10 2010-06-16 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20080311043A1 (en) * 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
KR101396797B1 (ko) 2006-06-30 2014-05-26 애브비 바이오테크놀로지 리미티드 자동 주사 장치
SG174804A1 (enExample) 2006-09-13 2011-10-28 Abbott Lab
AU2007318120B2 (en) 2006-10-27 2013-07-25 Abbvie Biotechnology Ltd Crystalline anti-hTNFalpha antibodies
US20100113294A1 (en) * 2007-04-16 2010-05-06 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
JP5576115B2 (ja) 2007-04-26 2014-08-20 中外製薬株式会社 高濃度アミノ酸含有培地を用いた細胞の培養方法
EP2679996A1 (en) * 2007-05-31 2014-01-01 AbbVie Inc. Biomarkers predictive of the responsiveness to TNF-alfa inhibitors in autoimmune disorders
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
ES2941738T3 (es) * 2007-07-09 2023-05-25 Genentech Inc Prevención de la reducción de enlaces disulfuro durante la producción recombinante de polipéptidos
EP2173380A4 (en) * 2007-07-13 2011-08-31 Abbott Biotech Ltd METHOD AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa HEMMER
CA2697163A1 (en) 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
TWI629064B (zh) 2007-11-30 2018-07-11 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US8415094B2 (en) * 2007-12-21 2013-04-09 Jaffar Ali bin M. Abdullah Protein-free gamete and embryo handling and culture media products
CA2703997C (en) 2007-12-26 2017-04-04 Xencor, Inc. Fc variants with altered binding to fcrn
EP2238446A4 (en) * 2008-01-03 2011-07-20 Abbott Biotech Ltd PREDICTING THE LONG-TERM EFFECT OF A CONNECTION IN THE TREATMENT OF PSORIASIS
US8637312B2 (en) 2008-01-09 2014-01-28 Cellca Gmbh Mammalian culture media with polyamine and iron
EP2249809A1 (en) 2008-01-15 2010-11-17 Abbott GmbH & Co. KG Powdered protein compositions and methods of making same
US8318416B2 (en) 2008-08-08 2012-11-27 Biogen Idec Ma Inc. Nutrient monitoring and feedback control for increased bioproduct production
JP4883067B2 (ja) 2008-09-29 2012-02-22 株式会社日立プラントテクノロジー 培養装置及び培養方法
NZ592095A (en) * 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
WO2010078450A1 (en) 2008-12-30 2010-07-08 Baxter International Inc. Method of enhancing cell growth using alkyl-amine-n-oxide (aanox)
MX2011011541A (es) 2009-04-29 2012-02-28 Abbott Biotech Ltd Dispositivo de inyeccion automatico.
EP2427483B1 (en) * 2009-05-07 2015-03-11 Hemarina Novel heamoglobin and uses thereof
WO2010136515A1 (en) * 2009-05-28 2010-12-02 Boehringer Ingelheim International Gmbh Method for a rational cell culturing process
JP5921433B2 (ja) * 2009-07-24 2016-05-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 攪拌システム
NZ598677A (en) 2009-08-11 2014-06-27 Genentech Inc Production of proteins in glutamine-free cell culture media
RU2582401C2 (ru) 2009-12-15 2016-04-27 Эббви Байотекнолоджи Лтд Усовершенствованная пусковая кнопка для автоматического инъекционного устройства
US9921210B2 (en) 2010-04-07 2018-03-20 Momenta Pharmaceuticals, Inc. High mannose glycans
US20110262965A1 (en) * 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
JP5980772B2 (ja) * 2010-04-26 2016-08-31 ノバルティス アーゲー 改良型細胞培養培地
CN105056232A (zh) 2010-06-03 2015-11-18 阿布维生物技术有限公司 用于治疗化脓性汗腺炎(hs)的用途和组合物
HRP20180136T1 (hr) * 2010-07-08 2018-04-06 Baxalta GmbH POSTUPAK PROIZVODNJE REKOMBINANTNOG VISOKOMOLEKULSKOG vWF U KULTURI STANICA
SG187885A1 (en) * 2010-08-31 2013-03-28 Friesland Brands Bv Culture medium for eukaryotic cells
ES2601202T3 (es) 2010-11-11 2017-02-14 Abbvie Biotechnology Ltd Formulaciones liquidas de anticuerpos anti-TNT-alfa de alta concentración
WO2012103141A1 (en) 2011-01-24 2012-08-02 Abbott Biotechnology Ltd. Automatic injection devices having overmolded gripping surfaces
WO2012110435A1 (en) * 2011-02-14 2012-08-23 Basf Se Bio process additives
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
AU2012324495B2 (en) * 2011-10-21 2016-04-21 Pfizer Inc. Addition of iron to improve cell culture
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US20130281355A1 (en) * 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
CN104364369B (zh) 2012-05-02 2018-09-07 生命技术公司 哺乳动物细胞中使用独特的高密度生长和转染培养基与表达增强剂对的高产量瞬时表达
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
CA2883272A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AR093460A1 (es) * 2012-11-14 2015-06-10 Merck Patent Ges Mit Beschränkter Haftung Medios de cultivo celular
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
US20140199728A1 (en) * 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
AU2013381687A1 (en) * 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
EP2970916B1 (en) 2013-03-13 2021-04-14 Merck Sharp & Dohme Corp. Adapted lepidopteran insect cells for the production of recombinant proteins
US20140271633A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Mammalian cell culture performance through surfactant supplementation of feed media
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
EP2836515A1 (en) 2013-03-14 2015-02-18 AbbVie Inc. Low acidic species compositions and methods for producing and using the same
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
SG11201507365VA (en) 2013-03-14 2015-10-29 Abbvie Inc Low acidic species compositions and methods for producing the same using displacement chromatography
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
KR102418824B1 (ko) * 2013-10-14 2022-07-11 아레스 트레이딩 에스.아. 포유동물의 고성능 유가식 배양을 위한 신규 배지
CN106170298B (zh) 2013-10-16 2024-01-09 前瞻疗法公司 用于提高抗体稳定性的缓冲液制剂
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015095809A1 (en) * 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
EP2923707A1 (en) 2014-03-28 2015-09-30 Hemarina Blood substitute with respiratory pigment
CA2945390A1 (en) * 2014-04-10 2015-10-15 Bayer Healthcare Llc Compounded media powder formulation and method of preparation of liquid medium for cell culture
KR101699761B1 (ko) * 2014-05-23 2017-01-25 주식회사 비비에이치씨 플로로탄닌 분획물을 이용한 중간엽 줄기세포로부터 유도만능 줄기세포를 제조하는 방법
PT3926051T (pt) 2014-06-04 2024-06-20 Amgen Inc Métodos de colheita de culturas de células de mamíferos
EP3158077B1 (en) * 2014-06-18 2023-04-05 Medimmune, LLC Cell culture methods and media comprising n-acetylcysteine
US20170226552A1 (en) 2014-07-03 2017-08-10 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
US20160185848A1 (en) 2014-07-09 2016-06-30 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using sugars
US10435464B1 (en) 2014-09-05 2019-10-08 Coherus Biosciences, Inc. Methods for making recombinant proteins
AU2015369809B2 (en) 2014-12-22 2022-03-17 Genzyme Corporation Methods of culturing a mammalian cell
KR102007930B1 (ko) * 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
CN105820246A (zh) * 2015-01-07 2016-08-03 上海张江生物技术有限公司 一种新型重组抗TNFα嵌合单克隆抗体制备方法及用途
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
JP6812967B2 (ja) * 2015-03-30 2021-01-13 味の素株式会社 キレート化鉄を含む神経幹細胞用培地
CN106190948B (zh) * 2015-05-07 2020-09-25 上海津曼特生物科技有限公司 一种cho-s细胞半固体培养基及其配制方法与应用
CN105018425B (zh) * 2015-07-09 2018-09-28 广州白云山拜迪生物医药有限公司 一种无动物来源成分的外周血淋巴细胞培养基
US20170016043A1 (en) * 2015-07-13 2017-01-19 Life Technologies Corporation System and method for improved transient protein expression in cho cells
CN105441378A (zh) * 2015-12-22 2016-03-30 肇庆大华农生物药品有限公司 一种培养Vero细胞用的无血清培养基及其制备方法
CA3013336A1 (en) 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
US20190055513A1 (en) * 2016-02-22 2019-02-21 Agency For Science, Technology And Research Cell culture medium
JP6997079B2 (ja) * 2016-05-10 2022-01-17 三菱商事ライフサイエンス株式会社 培地用組成物
CN105794772A (zh) * 2016-05-16 2016-07-27 天津市中奥天元科技发展有限公司 一种无血清细胞冻存液
WO2018018613A1 (zh) 2016-07-29 2018-02-01 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
CN106635974B (zh) * 2016-10-19 2020-10-27 浙江译美生物科技有限公司 一种人脐带间充质干细胞的分离和培养方法
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
EA201900326A1 (ru) 2016-12-23 2019-11-29 Усовершенствованные способы повышения продуктивности антител в культурах клеток млекопитающих и сведения к минимуму агрегации в процессах выделения и очистки, получения композиций и стабильные композиции антител, полученные этими способами
CA3054593A1 (en) * 2017-03-31 2018-10-04 Boehringer Ingelheim International Gmbh Perfusion medium
US10280217B2 (en) 2017-09-19 2019-05-07 American Air Liquide, Inc. Cell culture additives and their use for increased bioprotein production from cells
CN107904200B (zh) * 2017-10-20 2018-10-16 通化东宝生物科技有限公司 一种表达阿达木单抗的联合培养基及其应用
IL274265B1 (en) 2017-11-01 2025-09-01 Chugai Pharmaceutical Co Ltd Variant and isoform of an antibody with attenuated biological activity
JP2021503290A (ja) * 2017-11-16 2021-02-12 ライフ テクノロジーズ コーポレーション 液体培地を作製するための合理化された方法
CN111406112A (zh) * 2017-11-30 2020-07-10 豪夫迈·罗氏有限公司 用于培养哺乳动物细胞的工艺
EP3492582A1 (en) 2017-12-01 2019-06-05 UCB Biopharma SPRL Cell culture methods
US11391725B2 (en) * 2018-03-16 2022-07-19 Genzyme Corporation Methods for improving cell viability in a production bioreactor
AU2019243848B2 (en) 2018-03-26 2025-01-02 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
JP2021524745A (ja) * 2018-05-24 2021-09-16 アレス トレーディング ソシエテ アノニム 糖タンパク質組成物の非フコシル化レベルを制御する方法
JP7419273B2 (ja) * 2018-07-03 2024-01-22 ブリストル－マイヤーズ スクイブ カンパニー 組換えタンパク質を製造する方法
EP3831932A4 (en) * 2018-07-27 2021-09-15 Ajinomoto Co., Inc. SUSPENSION CULTURE ADDITIVE, SUSPENSION CULTURE MEDIA AND SUSPENSION CULTURE METHOD FOR ANIMAL CELLS
CN109337861B (zh) * 2018-11-12 2021-06-25 友康恒业生物科技（北京）有限公司 一种支持产物高表达的cho细胞无血清培养基
CN114008191A (zh) * 2018-12-21 2022-02-01 格洛丽亚娜治疗公司 哺乳动物细胞培养物产生的神经胚素抗体
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
EP4056678A4 (en) * 2019-11-05 2023-12-06 Ajinomoto Co., Inc. Method for producing protein
TW202128991A (zh) 2019-12-06 2021-08-01 美商再生元醫藥公司 抗ｖｅｇｆ蛋白組成物及其製備方法
PE20230409A1 (es) 2019-12-31 2023-03-07 Air Protein Inc Composiciones alimenticias con alto contenido en proteinas
CN111233996A (zh) * 2020-01-20 2020-06-05 北京交通大学 一种将丁酸钠用于促进工程细胞株分泌表达rhIL-24的方法
EP4155389A3 (en) * 2020-03-31 2023-07-12 Cell Exosome Therapeutics Inc. Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent
JP7521738B2 (ja) * 2020-05-18 2024-07-24 キヤノン株式会社 目的細胞の生産方法、目的細胞による生産物の生産方法、および無血清培地
CN112592948B (zh) * 2020-12-16 2023-05-09 广州汉腾生物科技有限公司 动物细胞的灌流培养方法
WO2022154762A1 (en) * 2021-01-18 2022-07-21 Turgut İlaçlari A.Ş. Method of producing adalimumab
MX2023012193A (es) * 2021-04-14 2023-10-25 Genzyme Corp Metodos de cultivo de perfusion de una celula de mamifero.
TW202328442A (zh) * 2021-09-10 2023-07-16 美商安進公司 平臺宿主對ｉｇｆ—培養基之適應
KR102817880B1 (ko) * 2021-11-17 2025-06-10 주식회사 웰진 무혈청 세포 배양 배지 조성물 및 이의 용도
KR102817881B1 (ko) * 2021-11-17 2025-06-10 주식회사 웰진 저혈청 배지 첨가제 및 이의 용도
CN114230669B (zh) * 2021-12-24 2024-01-30 天士力生物医药股份有限公司 一种双特异性抗体的生产方法
EP4484567A1 (en) * 2022-02-21 2025-01-01 Chugai Seiyaku Kabushiki Kaisha Perfusion culture method
KR20250099169A (ko) * 2022-10-31 2025-07-01 삼성바이오에피스 주식회사 고농도 액체 배지 제조 방법
CN116064374A (zh) * 2023-02-27 2023-05-05 内蒙古奥普赛生物科技有限公司 一种即用型无菌mem液体培养基的制备方法及其产品
KR20240177497A (ko) * 2023-06-20 2024-12-27 (주)엑셀세라퓨틱스 세포 특성 맞춤형 배지 조성 설계 플랫폼
WO2025128949A1 (en) * 2023-12-14 2025-06-19 Nutrition & Biosciences Usa 1, Llc Protective effect of polysaccharides on cell cultures containing anti-foam agents
WO2025128955A1 (en) * 2023-12-14 2025-06-19 Nutrition & Biosciences Usa 1, Llc Effects of differing viscosity-grade cellulose derivatives on cellular growth
WO2025128947A1 (en) * 2023-12-14 2025-06-19 Nutrition & Biosciences Usa 1, Llc Combinations of polysaccharides and polyether surfactants
WO2025128951A1 (en) * 2023-12-14 2025-06-19 Nutrition & Biosciences Usa 1, Llc Cell culture media containing cellulose derivatives and associated method

Family Cites Families (217)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5045468A (en) 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6451983B2 (en) 1989-08-07 2002-09-17 Peptech Limited Tumor necrosis factor antibodies
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5110913A (en) 1990-05-25 1992-05-05 Miles Inc. Antibody purification method
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022545D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Culture medium
ATE366316T1 (de) 1991-03-18 2007-07-15 Univ New York Monoklonale und chimäre antikörper spezifisch für menschlichen tumornekrosefaktor
US20070298040A1 (en) 1991-03-18 2007-12-27 Centocor, Inc. Methods of treating seronegative arthropathy with anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US20060246073A1 (en) 1991-03-18 2006-11-02 Knight David M Anti-TNF antibodies and peptides of human tumor necrosis factor
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US20040120952A1 (en) 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
AU662752B2 (en) 1991-07-15 1995-09-14 Wellcome Foundation Limited, The Production of antibodies
EP0897983B1 (en) 1991-10-25 2003-05-07 Immunex Corporation Antibody against CD40-L
EP0666312A1 (en) 1994-02-08 1995-08-09 Wolfgang A. Renner Process for the improvement of mammalian cell growth
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5741705A (en) 1995-02-23 1998-04-21 Quest International Flavors & Food Ingredients Company, Division Of Indopco, Inc. Method for in vitro cell growth of eucaryotic cells using low molecular weight peptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
KR100453314B1 (ko) 1995-06-07 2004-12-17 임뮤넥스 코포레이션 Cd40l 돌연변이 단백질
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
AR005035A1 (es) 1995-12-11 1999-04-07 Merck Patent Ges Mit Beschränkter Haftung Procedimiento para preparar proteinas recombinantes en e. coli, mediante fermentacion con gran concentracion de celulas.
KR19990077015A (ko) 1996-01-11 1999-10-25 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 진핵 세포 발현 시스템을 위한 발현 증강 서열 요소 (ease)
KR100317188B1 (ko) 1996-02-09 2002-02-19 스타르크, 카르크 사람TNFα와결합하는사람항체
ES2180689T3 (es) 1996-04-19 2003-02-16 Nestle Sa Linea inmortalizada de celulas epiteliales del colon humano.
EP0954563B1 (en) 1996-10-10 2008-07-02 Invitrogen Corporation Animal cell culture media comprising plant-derived nutrients
US20040171152A1 (en) * 1996-10-10 2004-09-02 Invitrogen Corporation Animal cell culture media comprising non-animal or plant-derived nutrients
ES2335365T3 (es) 1996-11-27 2010-03-25 Genentech, Inc. Purificacion por afinidad de polipeptido en una matriz de proteina a.
US20020045207A1 (en) 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
AU1663599A (en) 1997-12-19 1999-07-12 Novo Nordisk A/S Method for producing heterologous proteins in eukaryotic cells on an industrial scale using nucleotide-manipulating agents
WO1999057246A1 (en) * 1998-05-01 1999-11-11 Life Technologies, Inc. Animal cell culture media comprising non-animal or plant-derived nutrients
ES2261589T3 (es) 1998-05-06 2006-11-16 Genentech, Inc. Composicion de anticuerpos anti-her2.
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
ES2316675T3 (es) * 1998-07-01 2009-04-16 Takara Bio Inc. Metodos de transferencia genica con retrovirus.
US6406909B1 (en) * 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
US6190523B1 (en) 1999-07-20 2001-02-20 Basf Corporation Electrocoat coating composition and process for electrocoating a substrate
ATE474052T1 (de) 1999-09-27 2010-07-15 Genentech Inc Verfahren zur herstellung von rekombinanten proteinen mittels inhibitoren von apoptose
JP4660046B2 (ja) 1999-10-13 2011-03-30 イミュネックス・コーポレーション 組換えタンパク質発現のためのベクターおよび方法
AR026743A1 (es) 1999-12-09 2003-02-26 Pharmacia Ab Produccion de peptidos
IL151131A0 (en) 2000-02-08 2003-04-10 Genentech Inc Improved galactosylation of recombinant glycoproteins
EP2332579A3 (en) 2000-02-10 2011-09-21 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
WO2001077362A1 (fr) * 2000-04-06 2001-10-18 Chugai Seiyaku Kabushiki Kaisha Dosage immunologique d'anticorps anti hm1 . 24
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
EP1175931A1 (en) 2000-07-25 2002-01-30 Computer Cell Culture Center S.A. Integration of high cell density bioreactor operation with ultra fast on-line downstream processing
US20050249735A1 (en) 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
US20060018907A1 (en) 2000-08-07 2006-01-26 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
AU2001294520A1 (en) 2000-08-21 2002-03-04 Clonex Development, Inc. Methods and compositions for increasing protein yield from a cell culture
US6693173B2 (en) 2000-12-26 2004-02-17 Alpha Therapeutic Corporation Method to remove citrate and aluminum from proteins
US20030096414A1 (en) 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
WO2002094192A2 (en) 2001-05-24 2002-11-28 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
DK1404428T3 (da) 2001-06-05 2006-10-30 Genetics Inst Llc Fremgangsmåder til oprensning af stærkt anioniske proteiner
JP2004532642A (ja) 2001-06-13 2004-10-28 ジェネンテック・インコーポレーテッド 動物細胞の培養方法と動物細胞でのポリペプチド産生
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
HUP0402158A2 (hu) 2001-10-02 2005-01-28 Novo Nordisk Health Care Ag Rekombináns fehérjék előállítási eljárása eukarióta sejtekben
MXPA04003798A (es) 2001-10-25 2004-07-30 Genentech Inc Composiciones de glicoproteina.
WO2003046162A2 (en) 2001-11-28 2003-06-05 Polymun Scientific Immunbiologische Forschung Gmbh Process for the production of polypeptides in mammalian cell cultures
RU2004119816A (ru) 2001-11-28 2006-01-10 Сандоз АГ (CH) Способ культивирования клеток
DE60231651D1 (de) 2001-12-21 2009-04-30 Immunex Corp Proteinreinigungsverfahren
US20030201229A1 (en) 2002-02-04 2003-10-30 Martin Siwak Process for prefiltration of a protein solution
JP4460302B2 (ja) 2002-02-05 2010-05-12 ジェネンテック インコーポレイテッド タンパク質精製法
CA2417689C (en) 2002-03-05 2006-05-09 F. Hoffmann-La Roche Ag Improved methods for growing mammalian cells in vitro
CA2480121C (en) 2002-03-27 2012-02-28 Immunex Corporation Methods for increasing polypeptide production
US20030190710A1 (en) 2002-03-28 2003-10-09 Devries Ruth L. Control of glycoforms in IgG
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
US20040029229A1 (en) 2002-05-20 2004-02-12 Reeves Philip J. High level protein expression system
MXPA05000552A (es) 2002-07-15 2005-04-28 Immunex Corp Metodos y medios para controlar la sialilacion de proteinas producidas por celulas de mamifero.
US6974681B1 (en) 2002-08-23 2005-12-13 Immunex Corporation Cell culture performance with vanadate
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
US7067279B1 (en) 2002-08-23 2006-06-27 Immunex Corporation Cell culture performance with betaine
US7208585B2 (en) 2002-09-18 2007-04-24 Genencor International, Inc. Protein purification
US6890736B1 (en) * 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
US20040071694A1 (en) 2002-10-14 2004-04-15 Devries Peter J. Erythropoietin receptor binding antibodies
DK1576182T4 (da) * 2002-12-23 2020-04-20 Bristol Myers Squibb Co Produktkvalitetsforbedring ved fremgangsmåde med dyrkning af pattedyreceller til proteinfremstilling
US7541164B2 (en) 2002-12-23 2009-06-02 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
PT1601697E (pt) 2003-02-28 2007-09-04 Lonza Biologics Plc Purificação de anticorpos através de proteína a e cromatografia de troca iónica.
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EP1623019B2 (en) 2003-05-15 2017-01-25 Wyeth LLC Restricted glucose feed for animal cell culture
JP4599355B2 (ja) 2003-07-28 2010-12-15 ジェネンテック， インコーポレイテッド プロテインａアフィニティークロマトグラフィーの間のプロテインａの浸出の低減
EP1651754B1 (en) * 2003-08-08 2007-04-11 Cambridge Antibody Technology Limited Myeloma cell culture in transferrin-free low iron medium
GB2404665B (en) 2003-08-08 2005-07-06 Cambridge Antibody Tech Cell culture
JP4740138B2 (ja) 2003-10-10 2011-08-03 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 真核生物細胞におけるポリペプチドの大規模生産方法及びそれに適した培養容器
US9469672B2 (en) 2003-10-27 2016-10-18 Wyeth Llc Removal of high molecular weight aggregates using hydroxyapatite chromatography
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
JP2008504009A (ja) 2003-12-23 2008-02-14 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 腫瘍壊死因子結合蛋白質を生産する方法
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
CN1238498C (zh) * 2004-02-12 2006-01-25 陈志南 动物细胞无血清悬浮培养工艺过程控制参数的方法
WO2005087915A2 (en) 2004-03-08 2005-09-22 Biovest International, Inc. Use of ethanolamine for enhancing cell growth in membrane systems
SE0400886D0 (sv) 2004-04-02 2004-04-02 Amersham Biosciences Ab Process of purification
US20060018902A1 (en) 2004-04-09 2006-01-26 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
CA2565414A1 (en) 2004-05-04 2005-11-24 Novo Nordisk Health Care Ag O-linked glycoforms of polypeptides and method to manufacture them
US20060001890A1 (en) * 2004-07-02 2006-01-05 Asml Holding N.V. Spatial light modulator as source module for DUV wavefront sensor
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
CN102794109B (zh) 2004-09-30 2015-10-07 拜耳医药保健有限公司 用于集成连续生产生物分子的装置和方法
WO2006050050A2 (en) 2004-10-29 2006-05-11 Centocor, Inc. Chemically defined media compositions
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
JP2006143601A (ja) 2004-11-16 2006-06-08 Yamato Yakuhin Kk 血液粘度低下剤
EP1851305B1 (en) 2005-02-11 2012-01-18 Novo Nordisk Health Care AG Production of a polypeptide in a serum-free cell culture liquid containing plant protein hydrolysate
EP1869065B1 (en) 2005-03-11 2020-05-06 Wyeth LLC A method of weak partitioning chromatography
US20090203055A1 (en) 2005-04-18 2009-08-13 Massachusetts Institute Of Technology Compositions and methods for RNA interference with sialidase expression and uses thereof
US7247457B2 (en) 2005-04-26 2007-07-24 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Detection and identification of enteroviruses by semi-nested amplification of the enterovirus VP1 protein
US20060275867A1 (en) 2005-06-03 2006-12-07 Veronique Chotteau Process
KR20080032065A (ko) 2005-06-03 2008-04-14 제넨테크, 인크. 푸코실화 수준이 조절된 항체의 생성 방법
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc SELF-BUFFING PROTEIN FORMULATIONS
MX2007015051A (es) 2005-06-17 2008-01-18 Wyeth Corp Metodos para purificar proteinas que contienen la region fc.
RS57549B1 (sr) 2005-08-26 2018-10-31 Ares Trading Sa Proces za pripremu glikoziliranog interferona beta
DE102005046225B4 (de) * 2005-09-28 2012-01-05 Cellca Gmbh Verbessertes Zellkulturmedium
AR058140A1 (es) 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
WO2007070315A2 (en) 2005-12-08 2007-06-21 Amgen Inc. Improved production of glycoproteins using manganese
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
WO2007136752A2 (en) 2006-05-19 2007-11-29 Glycofi, Inc. Erythropoietin compositions
WO2009017491A1 (en) 2006-06-14 2009-02-05 Smithkline Beecham Corporation Methods for purifying antibodies using ceramic hydroxyapatite
KR101495549B1 (ko) 2006-07-13 2015-02-25 와이어쓰 엘엘씨 당단백질의 생산
EP2059258B1 (en) 2006-09-08 2019-11-13 Wyeth LLC Arginine wash in protein purification using affinity chromatography
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
SG174804A1 (enExample) 2006-09-13 2011-10-28 Abbott Lab
WO2008036600A2 (en) 2006-09-18 2008-03-27 Genentech, Inc. Methods of protein production
ES2541546T3 (es) 2006-11-03 2015-07-21 Wyeth Llc Sustancias que inhiben la glucólisis en cultivo celular
US20110105734A1 (en) 2006-12-06 2011-05-05 Jcr Pharmaceuticals Co., Ltd. Method for production of human erythropoietin
MX2009009240A (es) 2007-03-02 2009-09-08 Wyeth Corp Uso de cobre y glutamato en el cultivo celular para la produccion de polipeptidos.
AU2008232902B2 (en) 2007-03-30 2013-10-03 Medlmmune, Llc Antibody formulation
CA2887752C (en) 2007-04-03 2020-03-24 Nico Luc Marc Callewaert Glycosylation of molecules
US20100113294A1 (en) 2007-04-16 2010-05-06 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
WO2008135498A2 (en) 2007-05-04 2008-11-13 Novo Nordisk A/S Prevention of protein degradation in mammalian cell cultures
EP1988101A1 (en) 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
AU2008251405B2 (en) 2007-05-11 2012-05-17 Amgen Inc. Improved feed media
US20100221823A1 (en) 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
ES2941738T3 (es) 2007-07-09 2023-05-25 Genentech Inc Prevención de la reducción de enlaces disulfuro durante la producción recombinante de polipéptidos
ES2657055T3 (es) 2007-08-09 2018-03-01 Wyeth Llc Uso de perfusión para mejorar la producción de un cultivo de células alimentado por lotes en biorreactores
EP3441402A1 (en) 2007-10-30 2019-02-13 Genentech, Inc. Antibody purification by cation exchange chromatography
TWI629064B (zh) 2007-11-30 2018-07-11 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
HUE036712T2 (hu) 2007-12-27 2018-07-30 Baxalta GmbH Sejttenyésztési eljárás
EP2238154B1 (en) 2008-01-18 2015-09-16 Bio-Rad Laboratories, Inc. Enhanced purification of phosphorylated and non-phosphorylated biomolecules by apatite chromatography
JP2011512875A (ja) 2008-03-11 2011-04-28 ジェネンテック， インコーポレイテッド 増強されたａｄｃｃ機能を有する抗体
PL2271382T3 (pl) 2008-04-15 2013-08-30 Grifols Therapeutics Inc Dwuetapowa ultrafiltracja/diafiltracja
WO2009135181A2 (en) 2008-05-02 2009-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US8318416B2 (en) 2008-08-08 2012-11-27 Biogen Idec Ma Inc. Nutrient monitoring and feedback control for increased bioproduct production
PL3604324T3 (pl) 2008-08-14 2024-07-01 Genentech, Inc. Sposoby usuwania zanieczyszczeń za pomocą chromatografii membranowej jonowymiennej z zastąpieniem macierzystego białka
EP2340305A1 (en) 2008-09-26 2011-07-06 Eureka Therapeutics, Inc. Cell lines and proteins with variant glycosylation pattern
WO2010051360A1 (en) 2008-10-31 2010-05-06 Wyeth Llc Purification of acidic proteins using ceramic hydroxyapatite chromatography
US20110236391A1 (en) 2008-12-09 2011-09-29 Hanns-Christian Mahler Method for obtaining an excipient-free antibody solution
BRPI0923541A2 (pt) 2008-12-22 2016-01-26 Hoffmann La Roche purificação de imunoglobulina
US9115181B2 (en) 2009-01-08 2015-08-25 Ge Healthcare Bio-Sciences Ab Separation method using single polymer phase systems
EP2403866B1 (en) 2009-03-05 2018-05-02 Biogen MA Inc. Purification of immunoglobulins
ES2573663T5 (es) 2009-03-27 2019-12-12 Asahi Kasei Medical Co Ltd Procedimiento para eliminar virus de una solución de anticuerpos monoclonales de concentración elevada
US8063189B2 (en) 2009-04-13 2011-11-22 Bristol-Myers Squibb Company Protein purification by citrate precipitation
CA2757079C (en) 2009-04-20 2015-05-19 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
WO2010136515A1 (en) 2009-05-28 2010-12-02 Boehringer Ingelheim International Gmbh Method for a rational cell culturing process
WO2010141855A1 (en) 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
MX367489B (es) 2009-07-06 2019-08-23 Genentech Inc Metodo para cultivar celulas eucarionticas.
JP5540095B2 (ja) 2009-07-24 2014-07-02 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗体製造の最適化
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
NZ597809A (en) 2009-08-06 2014-05-30 Genentech Inc Method to improve virus removal in protein purification
US20110053223A1 (en) 2009-08-14 2011-03-03 Robert Bayer Cell culture methods to make antibodies with enhanced adcc function
WO2011024025A1 (en) 2009-08-28 2011-03-03 Avesthagen Limited An erythropoietin analogue and a method thereof
EP3736338A1 (en) 2009-09-01 2020-11-11 F. Hoffmann-La Roche AG Enhanced protein purification through a modified protein a elution
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
WO2011049798A1 (en) 2009-10-20 2011-04-28 Merck Sharp & Dohme Corp. Use of mixed mode chromatography for the capture and purification of basic antibody products
EP2499973A1 (en) 2009-11-10 2012-09-19 Hitachi Medical Corporation Ultrasonic diagnosis device
US9096879B2 (en) 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
EP2507627A2 (en) 2009-12-04 2012-10-10 Momenta Pharmaceuticals, Inc. Antennary fucosylation in glycoproteins from cho cells
US8277649B2 (en) 2009-12-14 2012-10-02 General Electric Company Membranes and associated methods for purification of antibodies
PT2513134T (pt) 2009-12-18 2017-12-14 Novartis Ag Solução de lavagem e método para cromatografia de afinidade
US9921210B2 (en) 2010-04-07 2018-03-20 Momenta Pharmaceuticals, Inc. High mannose glycans
EP2563904B1 (en) 2010-04-26 2015-01-21 Novartis AG Improved cell culture medium
JP5980772B2 (ja) 2010-04-26 2016-08-31 ノバルティス アーゲー 改良型細胞培養培地
KR20190067277A (ko) 2010-05-28 2019-06-14 제넨테크, 인크. 락테이트 데히드로게나제 및 피루베이트 데히드로게나제 키나제의 발현의 하향조절에 의한 락테이트 수준의 감소 및 폴리펩티드 생산의 증가
CN103080300B (zh) 2010-08-05 2015-11-25 安姆根有限公司 增加细胞培养物的产率和活力的二肽
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
KR101898302B1 (ko) 2010-10-15 2018-09-13 제이씨알 파마 가부시키가이샤 당사슬의 비환원 말단이 만노오스 잔기인 당 단백질의 제조 방법
EP2450375A1 (en) 2010-11-09 2012-05-09 Sandoz Gmbh Cell culture medium and process for protein expression, said medium and process comprising a PAM inhibitor
WO2012078376A1 (en) 2010-12-08 2012-06-14 Amgen Inc. Ion exchange chromatography in the presence of an amino acid
KR101574864B1 (ko) 2010-12-21 2015-12-11 에프. 호프만-라 로슈 아게 이소폼이 농축된 항체 제제 및 그의 제조 방법
SG191874A1 (en) 2011-01-07 2013-08-30 Abbvie Inc Anti-il-12/il-23 antibodies and uses thereof
WO2012120500A2 (en) 2011-03-06 2012-09-13 Merck Serono S.A. Low fucose cell lines and uses thereof
BR112013024521A2 (pt) 2011-03-25 2019-09-24 Genentech Inc métodos de purificação de proteínas
EP2511293A1 (en) 2011-04-13 2012-10-17 LEK Pharmaceuticals d.d. A method for controlling the main complex N-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
EP2702143B1 (en) 2011-04-29 2018-06-06 Biocon Research Limited Methods for reducing accumulation of lactate during culturing and method for producing polypeptide
US20120283419A1 (en) 2011-05-03 2012-11-08 Avantor Performance Materials, Inc. Separation of protein monomers from aggregates by solid weak anion exchange support functionalized with amine moieties
US9562252B2 (en) 2011-05-13 2017-02-07 Biogen Ma Inc. Methods of preventing and removing trisulfide bonds
CA2952347A1 (en) 2011-07-01 2013-01-10 Amgen Inc. Mammalian cell culture
WO2013006461A1 (en) 2011-07-01 2013-01-10 Biogen Idec Ma Inc. Cholesterol-based media supplementals for cell culture
CN103717729B (zh) 2011-07-08 2017-11-21 动量制药公司 细胞培养方法
WO2013013013A2 (en) 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
CA2851053A1 (en) 2011-10-19 2013-04-25 Roche Glycart Ag Separation method for fucosylated antibodies
WO2013066707A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Chromatography process for resolving heterogeneous antibody aggregates

Also Published As

Publication number Publication date
CA2910619A1 (en) 2008-03-20
JP5878682B2 (ja) 2016-03-08
US20140134674A1 (en) 2014-05-15
NZ597334A (en) 2014-02-28
AU2007294731B2 (en) 2014-04-17
US9234032B2 (en) 2016-01-12
TW201516149A (zh) 2015-05-01
TW201346032A (zh) 2013-11-16
IL197444A0 (en) 2011-08-01
WO2008033517A9 (en) 2009-02-26
WO2008033517A3 (en) 2008-11-27
SG174804A1 (enExample) 2011-10-28
US20140206038A1 (en) 2014-07-24
JP2010503397A (ja) 2010-02-04
CA2842959A1 (en) 2008-03-20
US20150125905A1 (en) 2015-05-07
WO2008033517A2 (en) 2008-03-20
US20160186130A1 (en) 2016-06-30
US9284371B2 (en) 2016-03-15
US8093045B2 (en) 2012-01-10
EP2527425A1 (en) 2012-11-28
CN103276033A (zh) 2013-09-04
CN103397065A (zh) 2013-11-20
TW200831669A (en) 2008-08-01
CN101663390B (zh) 2013-10-23
SG192441A1 (enExample) 2013-08-30
US8663945B2 (en) 2014-03-04
SG10201510384UA (en) 2016-01-28
MY185872A (en) 2021-06-14
MY161866A (en) 2017-05-15
EP2064314A4 (en) 2009-12-30
AU2007294731A1 (en) 2008-03-20
NO20091439L (no) 2009-05-28
KR20140132017A (ko) 2014-11-14
NZ575328A (en) 2012-06-29
CN103555652A (zh) 2014-02-05
US20080227136A1 (en) 2008-09-18
TWI456062B (zh) 2014-10-11
EP2064314A2 (en) 2009-06-03
US20160039927A1 (en) 2016-02-11
JP2013230151A (ja) 2013-11-14
US20120077213A1 (en) 2012-03-29
RU2014110141A (ru) 2015-09-27
CN102337243A (zh) 2012-02-01
RU2518289C2 (ru) 2014-06-10
MX353340B (es) 2018-01-09
MY185040A (en) 2021-04-30
US8906646B2 (en) 2014-12-09
RU2009113613A (ru) 2010-10-20
MY185887A (en) 2021-06-14
CN103555651A (zh) 2014-02-05
EP2500413A1 (en) 2012-09-19
TWI548747B (zh) 2016-09-11
EP2532737A2 (en) 2012-12-12
KR20090074040A (ko) 2009-07-03
MX2009002748A (es) 2009-03-26
US20190225934A1 (en) 2019-07-25
MX345141B (es) 2017-01-18
CA2842966A1 (en) 2008-03-20
CA2842964A1 (en) 2008-03-20
TW201708537A (zh) 2017-03-01
BRPI0716762A2 (pt) 2013-09-24
CA2663442A1 (en) 2008-03-20
US10119118B2 (en) 2018-11-06
CN101663390A (zh) 2010-03-03
US20170130191A1 (en) 2017-05-11
JP2016000030A (ja) 2016-01-07
EP2532737A3 (en) 2013-03-27
US20150087024A1 (en) 2015-03-26
US20140134675A1 (en) 2014-05-15
US9073988B2 (en) 2015-07-07

Similar Documents

Publication Publication Date Title
MY185887A (en) Cell culture improvements
SG10201901417UA (en) Production of proteins in glutamine-free cell culture media
WO2009126858A3 (en) Materials and methods for improved immunoglycoproteins
MY157798A (en) Ethanol production in non-recombination hosts
UA103364C2 (ru) Способ ферментативного производства четырехатомных спиртов
MY181513A (en) Cell culture compositions and methods for polypeptide production
MY157111A (en) Recombinant microorganisms and methods of production thereof
WO2009114702A3 (en) Recombinant production of authentic human proteins using human cell expression systems
WO2008154014A3 (en) A method for culturing mammalian cells to improve recombinant protein production
GB2452456A (en) Cell growth medium
EP4477668A3 (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
NZ584893A (en) PORCINE DC-SIGN, ICAM-3 AND LSECtin AND USES THEREOF
MX2011013700A (es) Cepa talaromyces y composiciones de enzimas.
IN2015DN00255A (enExample)
WO2010048417A3 (en) Perfusion bioreactors, cell culture systems, and methods for production of cells and cell-derived products
MY147186A (en) Biofuel production by recombinant microorganisms
MX2010007716A (es) Combinacion de una proteina de fusion del anticuerpo-il-2 de anti-edb fibronectina y una molecula que se une a celulas b, progenitores de la celula b y/o sus contrapartes cancerigenas.
WO2008063675A3 (en) Endodermal progenitor cells
WO2010068897A3 (en) Stem cell enhanced protein products and uses thereof
WO2008085962A3 (en) Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants
PH12014502870A1 (en) Method of producing recombinant iduronate-2-sulfatase
WO2007130543A3 (en) Method for producing stable mammalian cell lines producing high levels of recombinant proteins
MX2009008422A (es) Proceso para la preparacion de alquilpiridinas de 5-(1-alquiltio)2-sustituidas.
MX2009007790A (es) Mejora del crecimiento celular.
WO2011085157A3 (en) Methods for in vitro oocyte maturation